Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization

Bioorganic & Medicinal Chemistry Letters(2020)10.1016/j.bmcl.2020.127453Source: DataRank Database

Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization is a research paper published in Bioorganic & Medicinal Chemistry Letters (2020). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.75)OA: greenTopics (69)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Shailaja Hegde ORCID,Robert F. Paulson ORCID,Jong K. Yun ORCID,Jeremy A. Hengst ORCID

Live enrichment

PubMed:32736077 PMC:PMC7541634 OpenAlex:https://openalex.org/W3045556365

NCI NIH HHS

Grant: P01 CA171983

National Institutes of Health

Grant: 5P01CA171983-05

Targeted Sphingolipid Metabolism for Treatment of AML

National Institutes of Health

FWCI

0.75

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2025

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7541634

publisherhttps://api.elsevier.com/content/article/PII:S0960894X20305643?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0960894X20305643?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.bmcl.2020.127453

Fields of Study

Sphingolipid Metabolism and SignalingMicrotubule and mitosis dynamicsProtein Degradation and Inhibitors0301 basic medicine0303 health sciences03 medical and health sciencesAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug DevelopmentDrug Screening Assays, AntitumorEnzyme InhibitorsHumansMicrotubulesMolecular StructurePhosphotransferases (Alcohol Group Acceptor)PolymerizationStructure-Activity RelationshipSphingosine Kinase

MeSH Terms

Drug DevelopmentSphingosine KinaseAntineoplastic AgentsCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorEnzyme InhibitorsHumansMicrotubulesStructure-Activity RelationshipMolecular StructurePhosphotransferases (Alcohol Group Acceptor)Cell Line, TumorCell ProliferationPolymerization

Keywords

Sphingosine kinaseChemistrySphingosineKinaseMyeloid leukemiaMicrotubule polymerizationMicrotubuleSphingosine kinase 1PharmacologyCancer researchBiochemistryCell biologySphingosine-1-phosphateBiologyTubulinReceptorSphingosine Kinase InhibitorDual-targeted InhibitorMicrotubule Polymerization DisruptorDose-Response Relationship, DrugMolecular StructureCell SurvivalAntineoplastic AgentsMicrotubulesPolymerizationPhosphotransferases (Alcohol Group Acceptor)Structure-Activity RelationshipDrug DevelopmentCell Line, TumorHumansDrug Screening Assays, AntitumorEnzyme InhibitorsCell Proliferation

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization

FAIR Checklist

Authors (4)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)